Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer
Prostate Cancer Stage I, Bladder Outlet Obstruction
About this trial
This is an interventional treatment trial for Prostate Cancer Stage I
Eligibility Criteria
Inclusion Criteria: Life expectancy >/= 10 years Low risk prostate cancer with minor institutional amendment of EAU guidelines: PSA < 10 ng/ml or up to 20 ng/ml if PSA density is more than 15% Stage T1, T2a. Gleason score <7 (ISUP grade 1) Bladder outlet obstruction: IPSS > 9 Peak flow rate (Qmax < 15) Imperative indication for BOO surgery Exclusion criteria: Patients who are not willing Patients with bladder dysfunction (cystopathy) or other infravesical cause of obstruction other than prostate
Sites / Locations
- Urology and nephrology center
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
Surveillance with medical treatment for bladder outlet obstruction
Surveillance with anatomical endoscopic enucleation of the prostate for bladder outlet obstruction
Patients with low-risk prostate cancer who were elected for active surveillance protocol will have only medical treatment for control of their lower urinary tract symptoms secondary to bladder outlet obstruction
Patients with low-risk prostate cancer who were elected for active surveillance protocol will be offered anatomical endoscopic enucleation of the prostate for control of their lower urinary tract symptoms secondary to bladder outlet obstruction